RESUMEN
PURPOSE OF REVIEW: Immunological factors are a major cause of kidney allograft loss. Calcineurin inhibitors (CNIs) have improved short-term kidney allograft survival; however, they in turn contribute to long-term kidney allograft loss from chronic CNI nephrotoxicity. Tolerance induction in transplantation can avoid the long-term adverse effects of immunosuppressive medications. This review aims to critically discuss recent efforts in inducing transplantation tolerance. RECENT FINDINGS: Tolerance induction mediated by chimerism has shown some promise in minimizing or even complete withdrawal of immunosuppressive treatments in kidney allograft recipients. There has been a number of approaches as varied as the number of centres conducting these trials. However, they can be grouped into those mediated by transient microchimerism and those facilitated by more stable macro or full donor chimerism. The success rates in terms of long-term drug-free graft survival has been limited in microchimerism-mediated tolerance induction approaches. Mixed macrochimerism of less than 50% donor may be unstable with mostly the recipient's native immune system overpowering the donor chimeric status.Tolerance induction leading to chimerism has been limited to living donor kidney transplantation and additional long-term outcomes are required. Furthermore, immune monitoring after tolerance induction has faced a limitation in studying due to a lack of sufficient study participants and appropriate study controls. SUMMARY: Tolerance induction is one of several strategies used to prolong kidney allograft survival, but it has not been routinely utilized in clinical practice. However, future applications from the trials to clinical practice remain limited to living donor kidney transplantation. Once further data regarding tolerance inductions exist and practicality becomes widely accepted, tolerance induction may shift the paradigm in the field of kidney transplantation to achieve the best possible outcome of 'One Organ for Life'.
Asunto(s)
Quimerismo , Supervivencia de Injerto , Tolerancia Inmunológica , Trasplante de Riñón , Insuficiencia Renal Crónica/cirugía , Aloinjertos/inmunología , Ensayos Clínicos como Asunto , Predicción , Refuerzo Inmunológico de Injertos/métodos , Refuerzo Inmunológico de Injertos/tendencias , Supervivencia de Injerto/efectos de los fármacos , Supervivencia de Injerto/inmunología , Humanos , Tolerancia Inmunológica/efectos de los fármacos , Tolerancia Inmunológica/inmunología , Inmunosupresores/efectos adversos , Inmunosupresores/inmunología , Inmunosupresores/uso terapéutico , Riñón/inmunología , Riñón/cirugía , Trasplante de Riñón/efectos adversos , Donadores Vivos , Acondicionamiento Pretrasplante , Tolerancia al Trasplante/efectos de los fármacos , Tolerancia al Trasplante/inmunologíaRESUMEN
Background: Bypass graft surgery remains to be an important treatment option for left main and multivessel coronary artery disease. Approximately 2% of saphenous vein grafts are lost immediately after the coronary artery bypass graft operations and 12% in the first month due to thrombosis. Aims: To administer one anticoagulant and two antiplatelet agents in a way that locally affects the vein graft before the bypass operation and to thereby analyse their effects on early graft thrombosis. Study Design: Animal experimentation. Methods: Since ticagrelor was used locally for the first time in this study, its efficacy in combination with other drugs (acetylsalicylic acid, acetylsalicylic acid and ticagrelor, and acetylsalicylic acid + ticagrelor + unfractionated heparin) was examined on rats including control (untreated) and sham (pluronic gel) group (n=14 for each group). Before the tunica adventitia layer of the femoral veins was bypassed to the femoral artery, it was coated with the drug-eluting pluronic F-127 gel. The presence or absence of thrombus in the vein graft samples was recorded under light microscopy. In vein graft preparations where thrombus was detected, the thrombus area (µm2) was calculated using the Axiovision software. Immunohistochemical staining was performed with the anti-rat von Willebrand factor polyclonal antibody kit. Results: The number of preparations containing thrombus was significantly lower in the acetylsalicylic acid + ticagrelor + unfractionated heparin group than in the acetylsalicylic acid, control, and sham groups, according to the comparisons made on the 1st and 3rd days (p=0.001 and 0.02, respectively). von Willebrand factor staining was significantly lower in the acetylsalicylic acid + ticagrelor + unfractionated heparin group than in the other groups on the 3rd day (p=0.005). Conclusion: Locally effective acetylsalicylic acid-ticagrelor-unfractionated heparin complex has been shown to significantly reduce thrombus formation in vein grafts in this experimental model. Local administration of these drugs, which are routinely administered orally just before stent implantations, on the vein graft before the bypass is performed can prevent the loss of vein grafts due to thrombus, thereby reducing the mortality and morbidity of these patients.
Asunto(s)
Aspirina/farmacología , Puente de Arteria Coronaria/normas , Refuerzo Inmunológico de Injertos/normas , Trombosis/prevención & control , Venas/efectos de los fármacos , Animales , Anticoagulantes/uso terapéutico , Aspirina/uso terapéutico , Puente de Arteria Coronaria/métodos , Modelos Animales de Enfermedad , Refuerzo Inmunológico de Injertos/métodos , Heparina/uso terapéutico , Patología/métodos , Inhibidores de Agregación Plaquetaria/farmacología , Inhibidores de Agregación Plaquetaria/uso terapéutico , Poloxámero/uso terapéutico , Ratas , Trombosis/tratamiento farmacológico , Ticagrelor/farmacología , Ticagrelor/uso terapéutico , Venas/anomalíasRESUMEN
BACKGROUND: Patients with broad HLA sensitization have poor access to donor organs, high mortality while waiting for kidney transplant, and inferior graft survival. Although desensitization strategies permit transplantation via lowering of donor-specific antibodies, the B cell-response axis from germinal center activation to plasma cell differentiation remains intact. METHODS: To investigate targeting the germinal center response and plasma cells as a desensitization strategy, we sensitized maximally MHC-mismatched rhesus pairs with two sequential skin transplants. We administered a proteasome inhibitor (carfilzomib) and costimulation blockade agent (belatacept) to six animals weekly for 1 month; four controls received no treatment. We analyzed blood, lymph node, bone marrow cells, and serum before desensitization, after desensitization, and after kidney transplantation. RESULTS: The group receiving carfilzomib and belatacept exhibited significantly reduced levels of donor-specific antibodies (P=0.05) and bone marrow plasma cells (P=0.02) compared with controls, with a trend toward reduced lymph node T follicular helper cells (P=0.06). Compared with controls, carfilzomib- and belatacept-treated animals had significantly prolonged graft survival (P=0.02), and renal biopsy at 1 month showed significantly reduced antibody-mediated rejection scores (P=0.02). However, four of five animals with long-term graft survival showed gradual rebound of donor-specific antibodies and antibody-mediated rejection. CONCLUSIONS: Desensitization using proteasome inhibition and costimulation blockade reduces bone marrow plasma cells, disorganizes germinal center responses, reduces donor-specific antibody levels, and prolongs allograft survival in highly sensitized nonhuman primates. Most animals experienced antibody-mediated rejection with humoral-response rebound, suggesting desensitization must be maintained after transplantation using ongoing suppression of the B cell response.
Asunto(s)
Abatacept/farmacología , Refuerzo Inmunológico de Injertos/métodos , Rechazo de Injerto/prevención & control , Trasplante de Riñón , Oligopéptidos/farmacología , Inhibidores de Proteasoma/farmacología , Animales , Linfocitos B/inmunología , Médula Ósea/inmunología , Receptores Coestimuladores e Inhibidores de Linfocitos T/efectos de los fármacos , Receptores Coestimuladores e Inhibidores de Linfocitos T/inmunología , Evaluación Preclínica de Medicamentos , Centro Germinal/inmunología , Supervivencia de Injerto , Histocompatibilidad , Memoria Inmunológica/efectos de los fármacos , Inmunosupresores/uso terapéutico , Isoanticuerpos/biosíntesis , Ganglios Linfáticos/inmunología , Activación de Linfocitos/efectos de los fármacos , Macaca mulatta , Masculino , Células Plasmáticas/inmunología , Cuidados Preoperatorios , Trasplante de Piel , Linfocitos T Colaboradores-Inductores/inmunologíaRESUMEN
Introduction: Although prone to a higher degree of ischemia reperfusion injury (IRI), the use of extended criteria donor (ECD) organs has become reality in transplantation. We therefore postulated that peri-operative perfusion of renal transplants with anti-human T-lymphocyte globulin (ATLG) ameliorates IRI and results in improved graft function. Methods: We performed a randomized, single-blinded, placebo-controlled trial involving 50 kidneys (KTx). Prior to implantation organs were perfused and incubated with ATLG (AP) (n = 24 kidney). Control organs (CP) were perfused with saline only (n = 26 kidney). Primary endpoint was defined as graft function reflected by serum creatinine at day 7 post transplantation (post-tx). Results: AP-KTx recipients illustrated significantly better graft function at day 7 post-tx as reflected by lower creatinine levels, whereas no treatment effect was observed after 12 months surveillance. During the early hospitalization phase, 16 of the 26 CP-KTx patients required dialysis during the first 7 days post-tx, whereas only 10 of the 24 AP-KTx patients underwent dialysis. No treatment-specific differences were detected for various lymphocytes subsets in the peripheral blood of patients. Additionally, mRNA analysis of 0-h biopsies post incubation with ATLG revealed no changes of intragraft inflammatory expression patterns between AP and CP organs. Conclusion: We here present the first clinical study on peri-operative organ perfusion with ATLG illustrating improved graft function in the early period post kidney transplantation. Clinical Trial Registration: www.ClinicalTrials.gov, NCT03377283.
Asunto(s)
Suero Antilinfocítico/administración & dosificación , Funcionamiento Retardado del Injerto/prevención & control , Refuerzo Inmunológico de Injertos/métodos , Supervivencia de Injerto/efectos de los fármacos , Trasplante de Riñón , Adulto , Anciano , Animales , Funcionamiento Retardado del Injerto/metabolismo , Funcionamiento Retardado del Injerto/patología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Conejos , Factores de TiempoRESUMEN
Stromal cell-derived factor-1α (SDF-1α) has been known to implicate in homing of MSCs, and resveratrol has been reported to have a positive influence on SDF-1 level in the site of injury. In this study, a combined strategy was applied to evaluate bone marrow-derived MSCs (BMSCs) homing to the rat model of liver cirrhosis induced by common bile duct ligation (CBDL): (1) pretreatment delivery of resveratrol into the cirrhotic liver, and (2) transplantation of ex vivo BMSC preconditioning with SDF-1α. BMSCs were preconditioned with 10 ng/µL SDF-1α for 1 h and then labeled with the CM-Dil. Cirrhosis was induced by CBDL. Animals received intraperitoneal injection of resveratrol for 7 days, started on day 28 of CBDL post-operative. On day 36 post-operative, 1 × 106 of SDF-1α-preconditioned BMSCs was injected via caudal vein. Animals were sacrificed at 72 h post-cell transplantation. Immunofluorescence and flow cytometry assessments showed that the BMSC+SDF+RV group had an increased rate of homing into the liver, but it had a decreased rate of homing into the lung and spleen, as compared with the other groups (P < 0.05). The BMSC+SDF+RV group showed high protein expression of SIRT1, but low protein expression of p53 in the liver (P < 0.05 vs other groups). CXCR4 and matrix metalloproteinase (MMP)-9 highly expressed in SDF-1α-preconditioned BMSCs in vitro, and that AKTs and CXCL12 expressed in injured liver undergoing resveratrol injection. Our findings suggest that reseveratrol pretreatment prior to SDF-1α preconditioning could be a promising strategy for designing cell-based therapies for liver cirrhosis.
Asunto(s)
Células de la Médula Ósea/metabolismo , Quimiocina CXCL12/farmacología , Refuerzo Inmunológico de Injertos/métodos , Cirrosis Hepática/terapia , Trasplante de Células Madre Mesenquimatosas , Células Madre Mesenquimatosas/metabolismo , Estilbenos/farmacología , Animales , Células de la Médula Ósea/patología , Modelos Animales de Enfermedad , Cirrosis Hepática/metabolismo , Cirrosis Hepática/patología , Masculino , Células Madre Mesenquimatosas/patología , Ratas , Ratas Sprague-Dawley , ResveratrolRESUMEN
Patients who are candidates for a second kidney transplant (SKT) frequently have a higher level of panel reactive antibodies (PRA). We assessed the allosensitisation change after a first graft failure (GF), its predictors and impact on retransplantat outcomes. We retrospectively selected 140 adult patients who received a SKT. Recipient and donor characteristics were analyzed. We defined the delta PRA (dPRA) as the difference between peak PRA before the SKT and first one (cohort median value=+10%). Logistic regression analysis was used to determine risk factors for dPRA≥10% and acute rejection (AR) in the SKT. Univariable and multivariable Cox analysis was applied to assess independent predictors of second GF. Risk factors for dPRA≥10% at SKT were AR (OR=2.57; P=0.022), first graft survival <1 year (OR=2.47; P=0.030) and ABDR HLA mismatch (OR=1.38 per each mismatch; P=0.038). AR in the SKT was associated with dPRA≥10% (OR=2.79; P=0.047). Induction with a lymphocyte-depleting agent had a protective effect (OR=0.23; P=0.010). SKT survival was lower (P=0.008) in patients with a dPRA≥10% (75.6%, 60.5% in dPRA≥10%; 88.6%, 88.6% in dPRA<10% patients at 5 and 10 years, post-transplant respectively). Multivariable Cox regression showed that dPRA≥10% (HR=2.38, P=0.042), delayed graft function (HR=2.82, P=0.006) and AR (HR=3.30, P=0.001) in the SKT were independent predictors of retransplant failure. This study shows that an increased allosensitisation at retransplant was associated with the degree of HLA mismatch and led to poorer outcomes. De-emphasis of HLA matching in current allocation policies may be undesirable, particularly in patients with a higher chance of needing a SKT (AU)
Los pacientes candidatos a un segundo trasplante de riñón (STR) tienen a menudo un nivel superior de panel reactivo de anticuerpos (PRA). Evaluamos el cambio de alosensibilización después de un primer fracaso del injerto, sus predictores y repercusión en los resultados del retrasplante. Elegimos retrospectivamente a 140 pacientes adultos que recibieron un STR. Analizamos las características de los receptores y de los donantes. Definimos el delta PRA (dPRA) como la diferencia entre el pico de PRA antes del STR y el primero (cohorte mediana=+10%). Se aplicó análisis de regresión logística para determinar los factores de riesgo para dPRA≥10% y rechazo agudo (RA) en STR y análisis univariado y multivariado de Cox para evaluar predictores independientes de fallo del retrasplante. Los factores de riesgo para dPRA≥10% fueron: RA (OR=2,57; p=0,022), supervivencia del primero injerto menor a un año (OR=2,47; p=0,030) e incompatibilidad HLA ABDR (OR=1,38 por cada mismatch; p=0,038). El RA en el STR fue asociado con dPRA≥10% (OR=2,79; p=0,047). La inducción con un agente depletor de linfocitos tuvo un efecto protector (OR=0,23; p=0,010). La supervivencia del STR fue menor en pacientes con dPRA≥10% (75,6; 60,5% en dPRA≥10%; y 88,6; 88,6% en dPRA<10%; a los 5 y 10 años). La regresión multivariada de Cox mostró que dPRA≥10% (HR=2,38; p=0,042), función retardada de injerto(HR=2,82; p=0.006) y RA (HR=3,30; p=0,001) en STR fueron factores predictores independientes de fracaso en el retrasplante. Este estudio muestra que un incremento en la alosensibilización de retrasplante se ha asociado con el grado de incompatibilidad HLA y puede conducir a resultados más pobres en STR. La falta de énfasis en la compatibilidad de HLA en las políticas actuales de asignación puede no ser deseable, especialmente en pacientes con una mayor probabilidad de necesitar un STR (AU)
Asunto(s)
Humanos , Trasplante de Riñón/métodos , Refuerzo Inmunológico de Injertos/métodos , Rechazo de Injerto/inmunología , Reoperación/métodos , Histocompatibilidad/inmunologíaRESUMEN
Bone marrow (BM) aspirates, mobilized peripheral blood, and umbilical cord blood (UCB) have developed as graft sources for hematopoietic stem and progenitor cells (HSPCs) for stem cell transplantation and other cellular therapeutics. Individualized techniques are necessary to enhance graft HSPC yields and cell quality from each graft source. BM aspirates yield adequate CD34+ cells but can result in relative delays in engraftment. Granulocyte colony-stimulating factor (G-CSF)-primed BM HSPCs may facilitate faster engraftment while minimizing graft-versus-host disease in certain patient subsets. The levels of circulating HSPCs are enhanced using mobilizing agents, such as G-CSF and/or plerixafor, which act via the stromal cell-derived factor 1/C-X-C chemokine receptor type 4 axis. Alternate niche pathway mediators, including very late antigen-4/vascular cell adhesion molecule-1, heparan sulfate proteoglycans, parathyroid hormone, and coagulation cascade intermediates, may offer promising alternatives for graft enhancement. UCB grafts have been expanded ex vivo with cytokines, notch-ligand, or mesenchymal stromal cells, and most studies demonstrated greater quantities of CD34+ cells ex vivo and improved short-term engraftment. No significant changes were observed in long-term repopulating potential or in patient survival. Early phase clinical trials using nicotinamide and StemReginin1 may offer improved short- and long-term repopulating ability. Breakthroughs in genome editing and stem cell reprogramming technologies may hasten the generation of pooled, third-party HSPC grafts. This review elucidates past, present, and potential future approaches to HSPC graft optimization.
Asunto(s)
Técnicas de Reprogramación Celular/métodos , Refuerzo Inmunológico de Injertos/métodos , Supervivencia de Injerto , Trasplante de Células Madre Hematopoyéticas , Células Madre Hematopoyéticas/metabolismo , Aloinjertos , Animales , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , HumanosRESUMEN
We previously reported that exposure to a high hydrostatic pressure (HHP) of 200 MPa could completely inactivate porcine skin without damaging the extracellular matrix. In this study, we used an autologous porcine skin graft model and explored whether the skin inactivated by HHP could be engrafted without inflammation to the residual cellular components. Twenty-one full-thickness skin grafts of 1.5 × 1.5 cm in size were prepared from a minipig (n = 2). Grafts were either nonpressurized or pressurized to 100, 150, 200, 300, 500, or 1000 MPa (n = 3) and randomly implanted on the fascia and removed at 1 and 4 weeks after grafting. All grafts showed complete engraftment at the macroscopic level and microcirculation was detected by a full-field laser speckle perfusion imager. The epidermis was removed and skin appendages were not observed in the grafts pressurized to more than 200 MPa. Azan and Elastica van Gieson staining showed no sign of dermal collagen fiber degeneration, while elastin fibers were observed. The fibroblasts and capillaries were observed to have infiltrated to dermis in all groups without severe inflammation. In conclusion, we showed that skin inactivated by HHP up to 1000 MPa could be engrafted successfully without removing cellular remnants. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 1091-1101, 2017.
Asunto(s)
Dermis , Refuerzo Inmunológico de Injertos/métodos , Trasplante de Piel , Animales , Autoinjertos , Capilares/metabolismo , Capilares/patología , Colágeno/metabolismo , Dermis/irrigación sanguínea , Dermis/metabolismo , Dermis/patología , Elastina/metabolismo , Presión Hidrostática , PorcinosRESUMEN
Umbilical cord blood (UCB) transplantation is associated with long periods of aplastic anaemia. This undesirable situation is due to the low cell dose available per unit of UCB and the immaturity of its progenitors. To overcome this, we present a cell culture strategy aimed at the expansion of the CD34+ population and the generation of granulocyte lineage-committed progenitors. Two culture products were produced after either 6 or 14days of in vitro expansion, and their characteristics compared to non-expanded UCB CD34+ controls in terms of phenotype, colony-forming activity and multilineage repopulation potential in NOD-scid IL2Rγnull mice. Both expanded cell products maintained rapid SCID repopulation activity similar to the non-expanded control, but 14-day cultured cells showed impaired long term SCID repopulation activity. The process was successfully scaled up to clinically relevant doses of 89×106 CD34+ cells committed to the granulocytic lineage and 3.9×109 neutrophil precursors in different maturation stages. Cell yields and biological properties presented by the cell product obtained after 14days in culture were superior and therefore this is proposed as the preferred production setup in a new type of dual transplant strategy to reduce aplastic periods, producing a transient repopulation before the definitive engraftment of the non-cultured UCB unit. Importantly, human telomerase reverse transcriptase activity was undetectable, c-myc expression levels were low and no genetic abnormalities were found, as determined by G-banding karyotype, further confirming the safety of the expanded product.
Asunto(s)
Trasplante de Células Madre de Sangre del Cordón Umbilical/métodos , Sangre Fetal/citología , Anemia Aplásica/sangre , Anemia Aplásica/etiología , Anemia Aplásica/prevención & control , Animales , Antígenos CD34/sangre , Biotecnología , Diferenciación Celular , Linaje de la Célula , Ensayo de Unidades Formadoras de Colonias , Trasplante de Células Madre de Sangre del Cordón Umbilical/efectos adversos , Femenino , Sangre Fetal/inmunología , Refuerzo Inmunológico de Injertos/métodos , Granulocitos/citología , Humanos , Subunidad gamma Común de Receptores de Interleucina/deficiencia , Subunidad gamma Común de Receptores de Interleucina/genética , Ratones , Ratones Endogámicos NOD , Ratones Noqueados , Ratones SCID , Neutrófilos/citologíaRESUMEN
We identified the characteristics of myeloid-derived suppressor cells (MDSCs) and investigated their mechanism of induction and their functional role in allograft rejection using a murine corneal allograft model. In mice, MDSCs coexpress CD11b and myeloid differentiation antigen Gr-1. Gr-1+CD11b+ cells infiltrated allografted corneas between 4 d and 4 wk after surgery; however, the frequencies of Gr-1+CD11b+ cells were not different between accepted and rejected allografts or in peripheral blood or BM. Of interest, Gr-1intCD11b+ cells, but not Gr-1hiCD11b+ cells, infiltrated the accepted graft early after surgery and expressed high levels of immunosuppressive cytokines, including IL-10, TGF-ß, and TNF-related apoptosis-inducing ligand. This population remained until 4 wk after surgery. In vitro, only high dose (>100 ng/ml) of IFN-γ plus GM-CSF could induce immunosuppressive cytokine expression in Gr-1intCD11b+ cells. Furthermore, adoptive transfer of Gr-1intCD11b+ cells reduced T cell infiltration, which improved graft survival. In conclusion, high-dose IFN-γ in allograft areas is essential for development of Gr-1intCD11b+ MDSCs in corneal allografts, and subtle environmental changes in the early period of the allograft can result in a large difference in graft survival.
Asunto(s)
Trasplante de Córnea , Refuerzo Inmunológico de Injertos/métodos , Células Supresoras de Origen Mieloide/inmunología , Traslado Adoptivo , Aloinjertos/inmunología , Animales , Antígenos Ly/análisis , Apoptosis , Antígeno CD11b/análisis , Citocinas/biosíntesis , Rechazo de Injerto/inmunología , Supervivencia de Injerto , Factor Estimulante de Colonias de Granulocitos y Macrófagos/farmacología , Inmunofenotipificación , Interferón gamma/farmacología , Subgrupos Linfocitarios/citología , Subgrupos Linfocitarios/inmunología , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Células Supresoras de Origen Mieloide/clasificación , Células Supresoras de Origen Mieloide/trasplante , Quimera por RadiaciónRESUMEN
Clinical cord blood (CB) hematopoietic cell transplantation (HCT) has progressed well since the initial successful CB HCT that saved the life of a young boy with Fanconi anemia. The recipient is alive and well now 28 years out since that first transplant with CB cells from his HLA-matched sister. CB HCT has now been used to treat over 35,000 patients with various malignant and non-malignant disorders mainly using HLA-matched or partially HLA-disparate allogeneic CB cells. There are advantages and disadvantages to using CB for HCT compared to other sources of transplantable hematopoietic stem (HSC) and progenitor (HPC) cells. One disadvantage of the use of CB as a source of transplantable HSC and HPC is the limited number of these cells in a single CB collected, and slower time to neutrophil, platelet and immune cell recovery. This review describes current attempts to: increase the collection of HSC/HPC from CB, enhance the homing of the infused cells, ex-vivo expand numbers of collected HSC/HPC and increase production of the infused CB cells that reach the marrow. The ultimate goal is to manipulate efficiency and efficacy for safe and economical use of single unit CB HCT.
Asunto(s)
Trasplante de Células Madre de Sangre del Cordón Umbilical/métodos , Anemia de Fanconi/terapia , Refuerzo Inmunológico de Injertos/métodos , Supervivencia de Injerto , Femenino , Humanos , MasculinoRESUMEN
BACKGROUND: Stearic acid is known as a potent anti-inflammatory lipid. This fatty acid has profound and diverse effects on liver metabolism. The aim of this study was to investigate the effect of stearic acid on markers of hepatocyte transplantation in rats with acetaminophen (APAP)-induced liver damage. METHODS: Wistar rats were randomly assigned to 10-day treatment. Stearic acid was administered to the rats with APAP-induced liver damage. The isolated liver cells were infused intraperitoneally into rats. Blood samples were obtained to evaluate the changes in the serum liver enzymes, including activities of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) and the level of serum albumin. To assess the engraftment of infused hepatocytes, rats were euthanized, and the liver DNA was used for PCR using sex-determining region Y (SRY) primers. RESULTS: The levels of AST, ALT and ALP in the serum of rats with APAP-induced liver injury were significantly increased and returned to the levels in control group by day six. The APAP-induced decrease in albumin was significantly improved in rats through cell therapy, when compared with that in the APAP-alone treated rats. SRY PCR analysis showed the presence of the transplanted cells in the liver of transplanted rats. CONCLUSION: Stearic acid-rich diet in combination with cell therapy accelerates the recovering of hepatic dysfunction in a rat model of liver injury.
Asunto(s)
Antiinflamatorios/uso terapéutico , Tratamiento Basado en Trasplante de Células y Tejidos/métodos , Refuerzo Inmunológico de Injertos/métodos , Supervivencia de Injerto/efectos de los fármacos , Hígado/lesiones , Ácidos Esteáricos/uso terapéutico , Acetaminofén/toxicidad , Alanina Transaminasa/sangre , Alanina Transaminasa/metabolismo , Fosfatasa Alcalina/sangre , Fosfatasa Alcalina/metabolismo , Animales , Aspartato Aminotransferasas/sangre , Aspartato Aminotransferasas/metabolismo , Femenino , Hepatocitos/efectos de los fármacos , Hepatocitos/trasplante , Hígado/efectos de los fármacos , Hígado/patología , Masculino , Estrés Oxidativo/efectos de los fármacos , Ratas , Ratas Wistar , Albúmina Sérica/análisisRESUMEN
We are entering a very exciting era in umbilical cord blood transplantation (UCBT), where many of the associated formidable challenges may become treatable by ex vivo graft manipulation and/or adoptive immunotherapy utilizing specific cellular products. We envisage the use of double UCBT rather than single UCBT for most patients; this allows for greater ability to treat larger patients as well as to manipulate the graft. Ex vivo expansion and/or fucosylation of one cord will achieve more rapid engraftment, minimize the period of neutropenia and also give certainty that the other cord will provide long-term engraftment/immune reconstitution. The non-expanded (and future dominant) cord could be chosen for characteristics such as better HLA matching to minimize GvHD, or larger cell counts to enable part of the unit to be utilized for the development of specific cellular therapies such as the production of virus-specific T-cells or chimeric-antigen receptor T-cells which are reviewed in this study.
Asunto(s)
Trasplante de Células Madre de Sangre del Cordón Umbilical , Refuerzo Inmunológico de Injertos/métodos , Supervivencia de Injerto , Enfermedad Injerto contra Huésped/prevención & control , Ingeniería de Tejidos/métodos , HumanosRESUMEN
The high variability of the human leukocyte antigen (HLA) remains a major obstacle to the application of allogeneic products in cell-based therapies. We have developed a strategy to decrease the immunogenicity of cell and tissues to improve their survival after allogeneic transplantation in the absence of immunosuppression. Using RNA interference technology, the expression of HLA class I and II was stably downregulated. HLA-silenced cells demonstrated to prevent a de novo and escape a pre-formed alloimmune response in vitro and in vivo. Also, they demonstrated to be capable of engraft and survive after allogeneic transplantation independently of the donor's and recipient's genetic background. The generation of HLA-universal cells has may open new horizons in the field of regenerative medicine. Some of the potential clinical applications of HLA universal cells will be discussed in this review.
Asunto(s)
Refuerzo Inmunológico de Injertos/métodos , Antígenos HLA/inmunología , Histocompatibilidad , Células Madre Pluripotentes Inducidas/inmunología , Interferencia de ARN , ARN Interferente Pequeño/genética , Ingeniería de Tejidos/métodos , Inmunología del Trasplante , Aloinjertos , Plaquetas/citología , Plaquetas/inmunología , Prótesis Vascular , Células Cultivadas , Trasplante de Córnea , Regulación hacia Abajo , Células Endoteliales/citología , Células Endoteliales/inmunología , Supervivencia de Injerto , Antígenos HLA/biosíntesis , Antígenos HLA/genética , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/inmunología , Humanos , Transfusión de Plaquetas , Subgrupos de Linfocitos T/inmunología , Trombopoyesis , Andamios del TejidoRESUMEN
Islet transplantation is a treatment modality for diabetes mellitus that can maintain insulin levels within a physiologically appropriate range. However, wider clinical application is limited by insufficient donor numbers and a need for lifelong immunosuppression. Despite various clinical and preclinical trials, there is no single standard immunosuppressive regimen that can suppress acute and chronic immune reactions with lower toxicity to grafted islets. One of the strategies for overcoming lifelong immunosuppression is the incorporation of encapsulation technology, which can provide a physical immune barrier by keeping out high molecular weight immune system components, while still allowing low molecular weight oxygen, insulin and nutrients to pass through. Encapsulated islet transplantation approaches that have been studied so far include macroencapsulation, microencapsulation, conformal coating and nanoencapsulation. Herein we will review the basic concepts of islet encapsulation technique, earlier works to recent progress related to clinical studies and corporate investigations on encapsulated islet transplantation.
Asunto(s)
Diabetes Mellitus Tipo 1/terapia , Diabetes Mellitus Tipo 2/terapia , Trasplante de Islotes Pancreáticos/métodos , Animales , Diabetes Mellitus Tipo 1/inmunología , Diabetes Mellitus Tipo 1/cirugía , Diabetes Mellitus Tipo 2/inmunología , Diabetes Mellitus Tipo 2/cirugía , Refuerzo Inmunológico de Injertos/efectos adversos , Refuerzo Inmunológico de Injertos/métodos , Refuerzo Inmunológico de Injertos/tendencias , Humanos , Inyecciones Intraperitoneales , Trasplante de Islotes Pancreáticos/efectos adversos , Trasplante de Islotes Pancreáticos/inmunología , Trasplante de Islotes Pancreáticos/tendencias , Microtecnología , Nanotecnología/tendencias , Páncreas Artificial/efectos adversos , Páncreas Artificial/tendencias , Propiedades de Superficie , Trasplante Heterólogo/efectos adversos , Trasplante Heterólogo/métodos , Trasplante Heterólogo/tendencias , Trasplante Heterotópico/efectos adversos , Trasplante Heterotópico/métodos , Trasplante Heterotópico/tendenciasRESUMEN
The eSVS Mesh is a knitted wire lattice manufactured in cylindrical sheaths of various diameters, designed to be placed around the outer surface of a saphenous vein graft before use in coronary surgery. The goal is to improve long-term vein graft patency by preventing expansive endothelial injury obviating neointimal hyperplasia and subsequent graft atherosclerosis. Since the First-In-Man feasibility trial of the eSVS Mesh, postmarket studies in Europe and a feasibility trial in the United States are ongoing. Consensus from the principal investigators indicated the trials had confounding variables that may impact results other than evaluation of the eSVS Mesh alone. With input from these investigators, the recommended operative technique has been modified for future trials by removing the mesh from proximal and distal anastomoses and eliminating the use of fibrin sealant. These changes allow for use of an implant technique closer to standard vein bypass grafting and a more focused evaluation of the eSVS Mesh.
Asunto(s)
Puente de Arteria Coronaria/instrumentación , Prótesis e Implantes , Vena Safena/trasplante , Mallas Quirúrgicas , Puente de Arteria Coronaria/métodos , Adhesivo de Tejido de Fibrina , Refuerzo Inmunológico de Injertos/métodos , Oclusión de Injerto Vascular/prevención & control , Humanos , Grado de Desobstrucción VascularRESUMEN
BACKGROUND: Live kidney donation represents the gold standard for renal replacement therapy. Due to ABO and HLA incompatibility between donor and recipient pairs, one third of possible transplantations cannot be performed. Kidney exchange programs in combination with extracorporeal desensitization have been introduced to enable successful kidney transplantation in such circumstances. OBJECTIVE: This review discusses the current indications, methods, ethical problems and results within such programs. MATERIALS AND METHODS: Relevant Medline articles were analyzed and personal experiences of the authors are included in this article. RESULTS: Kidney exchange programs in combination with extracorporeal desensitization enable successful transplantation for most patients. DISCUSSION: The best combinations of existing strategies have to be defined and newly arisen ethical questions have to be answered.
Asunto(s)
Desensibilización Inmunológica/métodos , Refuerzo Inmunológico de Injertos/métodos , Fallo Renal Crónico/cirugía , Trasplante de Riñón/métodos , Obtención de Tejidos y Órganos/métodos , Sistema del Grupo Sanguíneo ABO , Incompatibilidad de Grupos Sanguíneos/inmunología , Incompatibilidad de Grupos Sanguíneos/terapia , Rechazo de Injerto/inmunología , Rechazo de Injerto/prevención & control , Antígenos HLA , Humanos , Técnicas de Inmunoadsorción , Terapia de Inmunosupresión/métodos , Fallo Renal Crónico/inmunología , Donadores Vivos , Plasmaféresis/métodosRESUMEN
BACKGROUND: Allograft dysfunction due to presumed antibody-mediated rejection (pAMR) is one of the most serious complications of heart transplantation. Combination therapies of high-dose steroids, intravenous immune globulin, and/or therapeutic plasma exchange (TPE) are often used in this setting. METHODS: We performed a 9-year retrospective review of all episodes of pAMR treated with TPE at our institution. pAMR diagnosis was based on clinical and pathologic findings. Left ventricular ejection fraction (LVEF) was measured at baseline, prior to initiation of TPE, and during the course of treatment. RESULTS: There were 42 patients with 47 episodes of pAMR treated with TPE. The majority of episodes were treated with three TPE; however, eight required only two TPE and five episodes required >3 TPE. All episodes of pAMR had LVEF measured before and after the series of TPEs. The mean pre-TPE LVEF was 38% compared with a post-therapy mean LVEF of 50% (P < 0.0001). In 16 episodes of pAMR, for which LVEF was measured following each apheresis, there was significant improvement of allograft function after the first TPE (pre-TPE mean LVEF of 31% and post-first TPE mean LVEF of 37%; P = 0.02). Incremental and significant improvement in allograft function continued following each TPE. Changes in human leukocyte antigen-donor specific antibodies and fibrinogen did not correlate with ejection fraction response. CONCLUSIONS: The rapid improvement in allograft function in our patients is most likely due to TPE as other pharmacologic interventions have longer onset. TPE should be considered a first-line intervention in the setting of pAMR.
Asunto(s)
Refuerzo Inmunológico de Injertos/métodos , Rechazo de Injerto/prevención & control , Trasplante de Corazón , Corazón/fisiopatología , Isoanticuerpos/inmunología , Intercambio Plasmático , Adolescente , Corticoesteroides/uso terapéutico , Adulto , Anciano , Aloinjertos , Niño , Femenino , Fibrinógeno/análisis , Rechazo de Injerto/etiología , Rechazo de Injerto/inmunología , Rechazo de Injerto/fisiopatología , Humanos , Inmunosupresores/uso terapéutico , Isoanticuerpos/sangre , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Volumen Sistólico , Adulto JovenRESUMEN
INTRODUCTION: The concern about nephrotoxicity with calcineurin inhibitors led to the search of novel agents for immunosuppression. Based on the requirement of T-cell co-stimulatory signals to fully activated naïve T cells, it became clear that blocking these pathways could be an appealing therapeutic target. However, some unexpected findings were noticed in the recent clinical trials of belatacept, including a higher rate of rejection, which warranted further investigation with some interesting concepts emerging from the bench. AREAS COVERED: This article aims to review the literature of the B7:CD28 co-stimulatory blockade in transplantation, including the basic immunology behind its development, clinical application and potential limitations. EXPERT OPINION: Targeting co-stimulatory pathways were found to be much more complex than initially anticipated due to the interplay between not only various co-stimulatory pathways but also various co-inhibitory ones. In addition, co-stimulatory signals have different roles in diverse immune cell types. Therefore, targeting CD28 ligands with cytotoxic T lymphocyte antigen-4 (CTLA4)-Ig may have some deleterious effects, including the inhibition of regulatory T cells, blockade of co-inhibitory signals (CTLA4) and promotion of Th17 cells. Co-stimulatory independence of memory T cells was another unforeseen limitation. Learning how to better integrate co-stimulatory targeting with other immunosuppressive agents will be critical for the improvement of long-term graft survival.
Asunto(s)
Antígenos CD28/antagonistas & inhibidores , Receptores Coestimuladores e Inhibidores de Linfocitos T/efectos de los fármacos , Inmunosupresores/uso terapéutico , Linfocitos T Citotóxicos/efectos de los fármacos , Inmunología del Trasplante , Abatacept , Animales , Antígeno B7-1 , Antígeno B7-2/antagonistas & inhibidores , Antígeno B7-2/inmunología , Antígenos CD28/agonistas , Antígenos CD28/inmunología , Ensayos Clínicos como Asunto , Ciclosporina/efectos adversos , Ciclosporina/uso terapéutico , Susceptibilidad a Enfermedades , Refuerzo Inmunológico de Injertos/métodos , Rechazo de Injerto/prevención & control , Supervivencia de Injerto/efectos de los fármacos , Humanos , Inmunoconjugados/efectos adversos , Inmunoconjugados/farmacología , Inmunoconjugados/uso terapéutico , Memoria Inmunológica/efectos de los fármacos , Inmunosupresores/efectos adversos , Inmunosupresores/farmacología , Infecciones/etiología , Enfermedades Renales/inducido químicamente , Enfermedades Renales/prevención & control , Activación de Linfocitos/efectos de los fármacos , Trastornos Linfoproliferativos/inducido químicamente , Terapia Molecular Dirigida , Estudios Multicéntricos como Asunto , Complicaciones Posoperatorias/inducido químicamente , Linfocitos T Citotóxicos/inmunología , Linfocitos T Reguladores/efectos de los fármacos , Linfocitos T Reguladores/inmunología , Células Th17/efectos de los fármacos , Células Th17/inmunologíaRESUMEN
Transplantation is the treatment of choice for end stage renal disease. Kidney transplants convey both a significant survival advantage to the individual recipient as well as cost savings to the medical system. Circulating alloantibodies directed against donor human leukocyte antigens and blood group antigens are fairly common among potential recipients. They are known to injure allografts, shorten allograft survival, and limit access to kidney transplantation. Hence, screening for pretransplant alloantibodies using complement dependent cytotoxic cross-matching and more sensitive techniques such as the solid phase assays, have become routine in an attempt to avoid incompatible donor-recipient pairs and risk stratify those with donor specific antibodies (DSA). By removing harmful antibodies, therapeutic apheresis (TA) has become a critical tool for improving access to transplantation in cases where the immunologic risk had previously been considered unacceptable. It has also allowed us to transplant across the barrier of ABO blood group incompatibility and expand the pool of donors with reasonable success. Furthermore, it is an important tool in the treatment of antibody-mediated rejection. Advanced apheresis technologies, such as immunoadsorption, and the use of TA in combination with innovative paired-donor exchange programs, offer the potential to further improve access and outcomes, minimizing the short comings of one single form of therapy alone.